FIELD: medicine.
SUBSTANCE: invention refers to medicine and aims at evaluating individual genetic risk of atherosclerosis. Blood is taken, recovering DNA and genetic typing of mitochondrial DNA. Presence of A1811G version indicates high genetic risk. Presence of T204C, G8251A, T10238C, G12501A versions indicates low genetic risk.
EFFECT: invention provides more accurate diagnosis of predisposition to atherosclerosis.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR MEASURING NUMBER OF COPIES OF HUMAN MITOCHONDRIAL DNA BY DIGITAL POLYMERASE CHAIN REACTION | 2021 |
|
RU2755663C1 |
| METHOD FOR PREDICTION OF CARDIOVASCULAR RISK BY MEANS OF ULTRASONIC ASSESSMENT OF SEVERITY OF ATHEROSCLEROSIS OF CAROTID AND FEMORAL ARTERIES | 2023 |
|
RU2837007C1 |
| MITOCHONDRIAL LOCALIZATION PEPTIDE, NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE CONTAINING ITS EXPRESSION VECTOR AND ITS USE | 2023 |
|
RU2817420C1 |
| METHOD FOR CORRECTION OF MITOCHONDRIAL DYSFUNCTION BY GENETIC CONSTRUCT | 2016 |
|
RU2642972C1 |
| NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE | 2023 |
|
RU2809065C1 |
| METHOD FOR DETERMINATION OF MTDNA SHARE WITH DELETIONS IN BIOLOGICAL SAMPLES | 2018 |
|
RU2676897C1 |
| TREATMENT OF MITOCHONDRIAL DISEASES | 2016 |
|
RU2745611C2 |
| METHOD OF DETERMINING DEGREE OF HETEROPLASMY MUTATIONS OF MITOCHONDRIAL GENOME | 2015 |
|
RU2600023C1 |
| DIAGNOSTICS FOR THE RISK OF DEVELOPMENT OF EITHER ATHEROSCLEROSIS OR DIABETIC RETINOPATHY | 2000 |
|
RU2238107C2 |
| TREATMENT OF MITOCHONDRIAL DISEASES | 2016 |
|
RU2834339C1 |
